indazoles has been researched along with Demyelinating Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atkinson, KC; Drew, A; Harris, NG; Hasselmann, JPC; Katzenellenbogen, JA; Kim, SH; Lee, JB; Obenaus, A; Soto, J; Tiwari-Woodruff, SK | 1 |
| Natarajan, C; Sriram, S; Yao, SY; Zhang, F | 1 |
2 other study(ies) available for indazoles and Demyelinating Diseases
| Article | Year |
|---|---|
Diffusion tensor imaging identifies aspects of therapeutic estrogen receptor β ligand-induced remyelination in a mouse model of multiple sclerosis.
Topics: Animals; Corpus Callosum; Cuprizone; Demyelinating Diseases; Diffusion Tensor Imaging; Disease Models, Animal; Estrogen Receptor beta; Female; Indazoles; Magnetic Resonance Imaging; Male; Mice; Multiple Sclerosis; Neuroprotective Agents; Remyelination | 2019 |
Activation of NOD2/RIPK2 pathway induces mitochondrial injury to oligodendrocyte precursor cells in vitro and CNS demyelination in vivo.
Topics: Animals; Animals, Newborn; Cerebral Cortex; Corpus Callosum; Demyelinating Diseases; Disease Models, Animal; Dose-Response Relationship, Drug; Electron Transport Complex I; Electron Transport Complex IV; Gene Expression Regulation; Indazoles; Mitochondria; Neuroprotective Agents; Nitric Oxide Synthase Type I; Nod2 Signaling Adaptor Protein; Oligodendroglia; Peptidoglycan; Rats; Receptor-Interacting Protein Serine-Threonine Kinase 2; Signal Transduction; Stem Cells; Time Factors | 2013 |